Company Shares of Rockwell Medical, Inc. Rally 10.82% - News Watch International PDF Print

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 10.82% in the past week and 32.8% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 10.75% and the outperformance increases to 34.62% for the last 4 weeks.

The company shares have rallied 18.51% in the past 52 Weeks. On June 12, 2015 The shares registered one year high of $13.35 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $10.74 and the 200 day moving average is recorded at $10.3. S&P 500 has rallied 8.07% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Friday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $13.23 and hit $13.35 on the upside , eventually ending the session at $13.32, with a gain of 1.76% or 0.23 points. The heightened volatility saw the trading volume jump to 419,890 shares. The 52-week high of the share price is $13.35 and the company has a market cap of $668 million. The 52-week low of the share price is at $8.095 . 18.55% of the shares are held by the company Insiders, 28% of the shares are held by the institutions. Company shares has an average 3 month share volume of 515,053 and an average 10 day volume is recorded to be 624,612 Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.